# 2025-03697: FDA shuts down sleep aid dreams for HETLIOZ capsules.

2025-03697, Notice of the Denial of a Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-07, effective 2025-02-28; PRIA reads it as touching household money (as of 2026-09-29).

- Canonical: https://policyrisk.com/federal-register/2025-03697
- As of: 2026-09-29
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-03697
- Title: Notice of the Denial of a Hearing Request Regarding a Proposal To Refuse To Approve a Supplemental New Drug Application for HETLIOZ (Tasimelteon)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 11542
- Published: 2025-03-07
- Effective: 2025-02-28
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-29

## In one line

FDA shuts down sleep aid dreams for HETLIOZ capsules.

## Summary

The FDA said no to Vanda Pharmaceuticals' request to approve HETLIOZ capsules for helping people who have trouble falling asleep. They also denied Vanda’s ask for a hearing to challenge this decision. This means the drug won’t be approved for this new use anytime soon, affecting patients hoping for a new insomnia treatment and Vanda’s plans to expand their product line.

## Abstract

The Food and Drug Administration (FDA) is announcing the availability of the decision to deny a request for a hearing regarding the proposal of the Center for Drug Evaluation and Research (CDER) to refuse to approve the supplemental new drug application (sNDA) 205677- 012, submitted by Vanda Pharmaceuticals, Inc. (Vanda), for HETLIOZ (tasimelteon) capsules, 20 milligrams (mg), for the treatment of insomnia characterized by difficulties with sleep initiation. The decision, which also refuses approval of sNDA 205677-012, is available in the docket identified by the number in the heading of this document.

## Effects PRIA read

- Refusal to Approve HETLIOZ for Insomnia: cost, medium. The FDA refused to approve supplemental NDA 205677-012 for HETLIOZ (tasimelteon) capsules, 20 mg, as a treatment for insomnia characterized by difficulties with sleep initiation, and denied Vanda Pharmaceuticals' request for a hearing. The FDA issued that decision on February 28, 2025, so HETLIOZ w…
- Existing HETLIOZ Approvals Remain: benefit, low. HETLIOZ (tasimelteon) remains approved under NDA 205677 (approved January 31, 2014) for non-24-hour sleep-wake disorder and under NDA 214517 (approved December 1, 2020) for nighttime sleep disturbances in pediatric patients with Smith-Magenis Syndrome. Those prior approvals are unchanged by the Feb…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-03697 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/07/2025-03697/notice-of-the-denial-of-a-hearing-request-regarding-a-proposal-to-refuse-to-approve-a-supplemental)
- [2025-03697 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-07/pdf/2025-03697.pdf)

## Related
- [Previous: 2025-03696, U.S. Integrated Ocean Observing System (IOOS®) Advisory Committee Public Meetin…](https://policyrisk.com/federal-register/2025-03696)
- [Next: 2025-03699, Arbitrator's Personal Data Questionnaire](https://policyrisk.com/federal-register/2025-03699)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-03697 (as of 2026-09-29).
